|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7,27,000 KRW | -0.68% |
|
-3.07% | -4.34% |
| 06/06 | Novartis, Roche, Biogen, Samsung Bioepis in Italy Eye-Medicine Probe | DJ |
| 31/05 | Samsung Biologics Aims to Lower Greenhouse Gas Emissions by 2030 | MT |
Samsung Biologics Co.,Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was KRW 28,708 million compared to KRW 47,962.94 million a year ago. Net income was KRW 179,361.79 million compared to KRW 141,755.37 million a year ago.
Basic earnings per share from continuing operations was KRW 2,520 compared to KRW 1,992 a year ago. Basic earnings per share was KRW 2,520 compared to KRW 1,992 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -4.34% | 37.55B | |
| +2.99% | 95.18B | |
| -10.41% | 33.75B | |
| +75.79% | 28.2B | |
| -14.61% | 15.63B | |
| -3.46% | 13.63B | |
| -12.31% | 11.5B | |
| +184.77% | 10.81B | |
| -54.13% | 9.23B | |
| +6.22% | 9.09B |
SAMSUNG BIOLOGICS CO.,LTD. 
